TBC1 domain family member 3 pseudogene 7Genealiases: []
Q-omics provides the consensus-scored TBC1D3P7 profile across patient tissues and cancer cell-line models. TBC1D3P7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TBC1D3P7 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, TBC1D3P7 RNA expression shows 6,566 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, BLCA, and STAD as cancer lineages where TBC1D3P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D3P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D3P7 survival associations across molecular data types. TBC1D3P7 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D3P7 RNA expression–survival associations across cancer types. High TBC1D3P7 expression shows unfavorable associations in MESO, LIHC, KIRC, UCEC, KICH and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TBC1D3P7 RNA expression.
This table summarizes TBC1D3P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D3P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D3P7 shows higher tumor expression in BLCA, KIRC, LUAD, LUSC, BRCA and HNSC. The BLCA box plot shows higher TBC1D3P7 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p = .009).
This table shows molecular features associated with TBC1D3P7 in patient tissues and cancer cell lines. In patient samples, TBC1D3P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
